Document Detail

Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML.
MedLine Citation:
PMID:  19270728     Owner:  NLM     Status:  MEDLINE    
We examined whether the use of G-CSF-primed unmanipulated bone marrow (pBM) permits successful transplantation in patients with adverse comorbid pretransplantation conditions. A total of 33 patients at variable risk of AML undergoing allogeneic SCT from an HLA-identical sibling participated. The patients suffered from a variety of treatment-related sequelae before SCT and many cases also featured the presence of major organ dysfunction. The median follow-up duration of patients who were among the overall survivors was 58 months (range, 11-125 months). The median number of CD34(+) cells infused was 3.5 x 10(6) per kg (range, 0.8-15.6 x 10(6) per kg). The median number of days for recovery of ANC and platelet count without transfusion was 13 (range, 6-22) and 18 (range, 11-29) days, respectively. Four patients (12%) died due to nonrelapse causes and only one patient developed the same course of infectious complication as before SCT. No particular finding in the context of CMV infection or other post transplant complication was observed. The estimated 10-year overall survival rate was 68%. Our results suggest that the use of pBM allows successful engraftment without increasing complications in patients with various comorbidities before transplantation.
H-J Kim; W-S Min; B-S Cho; K-S Eom; S-Y Kim; Y-J Kim; S Lee; C-K Min; S-G Cho; J-W Lee; C-C Kim
Related Documents :
24888538 - Does stapled anopexy for bleeding haemorrhoids cure associated anaemia?
24700518 - Dissection and identification of parathyroid glands during thyroidectomy: association w...
23855898 - Comparison of the baska(®) mask with the single-use laryngeal mask airway in low-risk f...
24391238 - Sighting characteristics and photo-identification of cuvier's beaked whales (ziphius ca...
25281478 - Trans-subscapularis portal versus low-anterior portal for low anchor placement on the i...
23725518 - Treatment of diabetic nephropathy with tripterygium wilfordii hook f extract: a prospec...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-09
Journal Detail:
Title:  Bone marrow transplantation     Volume:  44     ISSN:  1476-5365     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-23     Completed Date:  2009-12-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  345-51     Citation Subset:  IM    
Division of Hematology, Department of Internal Medicine, St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Weight
Bone Marrow / drug effects*
Bone Marrow Transplantation / adverse effects*,  methods
Confidence Intervals
Donor Selection
Follow-Up Studies
Graft vs Host Disease / prevention & control
Granulocyte Colony-Stimulating Factor / administration & dosage*
Hematopoietic Stem Cell Transplantation / adverse effects*,  methods
Leukemia, Myeloid, Acute / complications*,  mortality,  therapy*
Living Donors
Middle Aged
Quality of Life
Survival Analysis
Time Factors
Transplantation Conditioning*
Treatment Outcome
Young Adult
Reg. No./Substance:
143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner.
Next Document:  Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem ce...